Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.

Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. · 2024

Read Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. by Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11111408.txt.

Introduction

Holderfield and a large team describe a drug that blocks both mutant and normal forms of a cancer driver in this 2024 study. RAS genes are among the most mutated genes in cancer, with KRAS the worst offender. Approved drugs target only one mutant form, G12C, which covers about 15 percent of KRAS-mutated cancers. Most patients with other KRAS mutations have no approved option.

Their compound, RMC-7977, locks the active state of mutant and wild-type RAS in a three-part complex, the authors report. It hit RAS-driven tumours across many genotypes, above all those with codon 12 mutations. Tumours shrank in diverse animal models and the drug was well tolerated. It also slowed G12C models that had grown resistant to the older drugs. The team presents it as a broad-spectrum route for RAS-addicted cancers.

Catalog record

CREATORHolderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M.
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE85 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11111408

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy By Matthew Holderfield, Bianca J Lee, Jingjing Jiang, Aidan Tomlinson, Kyle J Seamon, Alessia Mira, Enrico Patrucco, Grace Goodhart, Julien Dilly, Yevgeniy Gindin, Nuntana Dinglasan, Yingyun Wang Published in: Nature DOI: 10.1038/s41586-024-07205-6 ABSTRACT Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12C mutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRAS mutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAS codon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12C cancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985). Subject terms: Targeted therapies, Drug development, Cancer therapeutic resistance MAIN RAS family genes encode small GTPase proteins that regulate cell proliferation in response to growth factor stimuli1,5. Cancer-associated KRAS mutations are found frequently in non-small cell lung cancer (NSCLC), colorectal cancers (CRC) and pancreatic ductal adenocarcinoma2 (PDAC), the three leading causes of cancer deaths in the USA6. These activating mutations drive tumour progression by stabilizing the active, GTP-bound (ON) state of RAS proteins and thereby increasing oncogenic flux through downstream effectors7. Analysis of CRISPR–Cas9 functional genetic screening data demonstrated that KRAS-mutated cancer cell lines are highly sensitive to disruption of the KRAS locus (Extended Data Fig. 1a), and KRAS mutation status was the only genetic feature that exhibited a significant correlation with KRAS dependency (Extended Data Fig. 1b). Similar results were observed for NRAS and HRAS in NRAS- and HRAS-mutated lines, respectively (Extended Data Fig. 1c–f). Furthermore, KRAS mutations at position 12 are both the most frequent KRAS alterations and are associated with the highest degree of KRAS dependency compared with other KRAS mutations (Extended Data Fig. 1g). This result suggests that although many mutations at KRAS codons 12, 13 and 61 have transforming potential8,9, not all KRAS mutations are associated with equivalent KRAS oncogene dependence. Additionally, these data suggest that the KRASG12X mutation is a genetic marker of RAS oncogene addiction and highlight a patient population that may derive a particularly large benefit from a targeted inhibitor of these oncogenic RAS variants. [Figure: Relationship between RAS gene effect and RAS mutation.a,c,e, Barplots ordered by KRAS (a), NRAS (c), or HRAS (e) CHRONOS score (CRISPR knockout gene effect from https://depmap.org). Each bar represents a cell line. KRAS, NRAS or HRAS mutant cells colored green, blue, or purple respectively. b,d,f, Gene mutation features from trained Random Forest regression model mapping gene mutation status to gene effect. Datapoints represent mutated genes, ordered by importance for the gene effect in each plot. Y-axis indicates the genetic feature importance for KRAS (b), NRAS (d), or HRAS (f) gene effect (see Methods). g, Mean KRAS Chronos score for each KRAS genotype is shown, with the mean effect score across all cell lines subtracted. P-values were calculated by a two-sided Wilcoxon rank sums test comparing the distribution of genotype effect to the distribution of effect scores outside of that genotype (Bonferonni-corrected p-value of 0.05/31 = 0.0016 indicated by a gray horizontal line, 31 KRAS genotypes tested, point size is proportional to sample size of each genotype, see methods). Source Data] RMC-7977 DISCOVERY AND DEVELOPMENT RAS proteins have historically been recalcitrant drug targets2,3, although progress in targeting the inactive, GDP-bound state of KRAS(G12C) has resulted in regulatory approvals for two drugs, sotorasib and adagrasib10,11. We recently described RMC-4998 and RMC-629112, two covalent tri-complex inhibitors that are designed to target the active state of KRAS(G12C). These macrocyclic compounds were derived from sanglifehrin A, a natural product that binds to cyclophilin A (CYPA) with high affinity13. The mechanism of action of these inhibitors is distinct from that of bifunctional immunophilin-binding inhibitors with independent RAS- and CYPA-binding motifs joined by a linker14, and instead reflects the binding mechanism of multiple natural products that inspired a paradigm for inhibiting undruggable targets15,16. Upon binding CYPA, tri-complex inhibitors remodel the surface of CYPA to create a binary complex with high affinity for active KRAS. Selectivity for KRAS(G12C) is achieved via covalent modification of the reactive thiol group introduced by the oncogenic mutation. The resulting CYPA–compound–KRAS tri-complex sterically blocks KRAS–effector interactions and disrupts downstream signalling. Most RAS oncoproteins with missense mutations are not amenable to selective covalent targeting but could be susceptible to non-covalent inhibition by tri-complex formation with CYPA. In a previous study, we identified compound 212 (referred to in the present Article as compound 1) (Fig. 1a) with weak, reversible binding to GMPPNP-bound wild-type KRAS and KRAS(G12C). We postulated that we could use structure-guided design to optimize compound 1 to generate a reversible, orally bioavailable inhibitor with broad activity against the active states of multiple RAS variants. Tri-complex formation requires two distinct binding events (Fig. 1b). First, the compound binds to CYPA to form the binary complex (with dissociation constant Kd1). The binary CYPA–compound complex then binds to active RAS (with dissociation constant Kd2) to form a tri-complex structure in which CYPA sterically occludes RAS–effector interactions (Extended Data Fig. 2a–d). Both binding events are essential for tri-complex formation, and we sought to optimize both Kd1 and Kd2 to increase the potency of RAS inhibition, focusing initially on KRAS(G12V) as a representative oncogenic mutant. [Figure: RMC-7977 inhibits the active state of multiple RAS variants.a, Compound structures. The CYPA-binding motif of compound 1 is highlighted in blue. b, Schematic of tri-complex formation showing reversible binding of RMC-7977 to CYPA (Kd1) and of the binary complex to RAS (Kd2). c, A through-water hydrogen bonding network is formed between the ether of RMC-7977 and the carbonyl of RAS Y32 (PDB ID: 8TBM). d, CYPA–RMC-7977 binding showing hydrogen bonds, involving R55, the piperazic acid moiety, F113, M61, the geminal dimethyl group, the pyridine and F60. The basic nitrogen of the piperazine forms a cation–π interaction with W121. e, Oriented by the hydrogen bond to CYPA W121, RAS Y64 forms π-stacking interactions with the pyridine and indole groups. Apolar sidechains on both SWI and SWII form hydrophobic interactions with RMC-7977. f, The tri-complex binding mode creates an open groove between CYPA, KRAS and RMC-7977 along the Q61–G12–G13 axis. g, This groove can accommodate the bulky sidechains found in oncogenic mutants, with residues Q61, G12 and G13 measuring 3.5, 7.5, and 9.7 Å, respectively, from RMC-7977

Read the complete text